Pyrotinib dimaleate Inhibitor

Name: Pyrotinib dimaleate Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5753753
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5753753

Pyrotinib dimaleate is a potent and selective dual inhibitor of EGFR/HER2 (IC50 s of 13 and 38nM, respectively). More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

Pyrotinib dimaleate, Inhibitor

Full Product Name

Pyrotinib dimaleate

Product Synonym Names

SHR-1258 dimaleate

Form/Format

Solid. Powder

Purity/Purification

98.00%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

815.22

Solubility

H2O: 106mg/mL (130.03mM)
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C40H39ClN6O11

SMILES

O=C(NC1=C(OCC)C=C2N=CC(C#N)=C(NC3=CC=C(OCC4=NC=CC=C4)C(Cl)=C3)C2=C1)/C=C/[C@@H]5N(C)CCC5.O=C(O)/C=C\C(O)=O.O=C(O)/C=C\C(O)=O

CAS Number

1397922-61-0

Target & IC50

HER2: ic50 38nM
EGFR: ic50 13nM

In Vitro

Pyrotinib dimaleate has favorable drug-like physicochemical properties and shows relatively higher oral exposure in human subjects (oral; t1/2=15 h) with a much longer half life than that of preclinical animal species such as mouse (i.v.; t1/2=1.56 h; i.g.; t1/2=2.52 h) and rat (i.v.; t1/2=4.42 h; i.g.; t1/2=3.38 h).Pyrotinib dimaleate has acceptable bioavailability of 20.6%, 43.5% and 13.5% in nude mice, rats and dogs, respectively.

Product Categories/Family for Pyrotinib dimaleate, inhibitor

Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors

Product References and Citations for Pyrotinib dimaleate, inhibitor

Li X, et al. Discovery and development of Pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment,of breast cancer. Eur J Pharm Sci. 2017 Jan 2pii: S0928-0987(17)30043-X.
Li X, et al. Discovery and development of Pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment,of breast cancer. Eur J Pharm Sci. 2017 Jan 21. pii: S0928-0987(17)30043-X.

Other Notes

Small volumes of Pyrotinib dimaleate, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Pyrotinib dimaleate purchase

MBS5753753 is an inhibitor targeting Pyrotinib dimaleate.